MedPath

ddcfDNA in Kidney Transplant Recipients

Recruiting
Conditions
Kidney Transplant Rejection
Registration Number
NCT06013358
Lead Sponsor
Seoul National University Hospital
Brief Summary

The objective of this study is to predict subclinical Antibody-Mediated Rejection (ABMR) occurrences in de novo DSA-positive recipients maintaining stable renal function after transplantation. This will be achieved through the measurement of donor-derived cell-free DNA. The utility of donor-derived cell-free DNA will be validated based on histological findings using Receiver Operating Characteristics (ROC) curve analysis.

Detailed Description

Not available

Recruitment & Eligibility

Status
RECRUITING
Sex
All
Target Recruitment
200
Inclusion Criteria
  • Recipients aged 18 and above
  • Patients with de novo DSA positivity post-kidney transplantation and stable renal function: De novo HLA DSAs encompass both class I and class II, with Mean Fluorescence Intensity (MFI) greater than 1000. Stable renal function is defined as serum creatinine variation of less than 15% compared to the last 6 months.
  • Patients with detected de novo HLA-DSAs but did not undergo histological examinations.
Exclusion Criteria
  • Multi-organ transplant recipients
  • Recipients with positive preformed DSAs
  • ABO-incompatible transplant recipients
  • Pediatric recipients under 18 years old at the time of transplantation
  • Recipients lost to follow-up observation
  • atients already subjected to histological examinations due to positive De novo HLA-DSAs.

Study & Design

Study Type
OBSERVATIONAL
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
diagnostic accuracy of subclinical ABMR10 years within kidney transplantation
Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (1)

Seoul National University Hospital

🇰🇷

Seoul, Korea, Republic of

© Copyright 2025. All Rights Reserved by MedPath